DiscGenics ( 
https://c212.net/c/link/?t=0&l=en&o=3404974-1&h=3114304150&u=https%3A%2F%2Fwww.discgenics.com%2F&a=DiscGenics 
), Inc., a privately held, clinical stage biopharmaceutical company focused on 
developing regenerative cell-based therapies that alleviate pain and restore 
function in patients with degenerative diseases of the spine, today announced 
that Chief Executive Officer and Chairman Flagg Flanagan will present at the 
40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 
9:00 a.m. EST.

Logo - https://mma.prnewswire.com/media/561675/DiscGenics_Logo.jpg 

Invited attendees of the Conference can access the virtual session for both 
live and on demand replay.

About DiscGenics

DiscGenics is a privately held, clinical stage biopharmaceutical company 
focused on developing regenerative cell-based therapies that alleviate pain and 
restore function in patients with degenerative diseases of the spine. As the 
only company in the world to develop an allogeneic cell therapy derived from 
intervertebral disc cells to treat diseases of the disc, DiscGenics believes it 
has a unique opportunity to harness the restorative potential of the human body 
to heal millions of patients suffering from the debilitating effects of back 
pain. DiscGenics' first product candidate, IDCT, is a homologous, allogeneic, 
injectable cell therapy that utilizes biomedically engineered progenitor cells 
derived from intervertebral disc tissue, known as Discogenic Cells, to offer a 
non-surgical, potentially regenerative solution for the treatment of patients 
with mild to moderate degenerative disc disease. For more information, visit 
www.discgenics.com.

SOURCE: DiscGenics, Inc.

CONTACT: Lindsey Saxon, lindsey@discgenics.com; Colin Novick (Japan), 
colin.lee.novick@cj-partners.com